Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 4895 (118th)

Lowering Drug Costs for American Families Act

referredUnited States· United States Congress· EN

Introduced

26 July 2023

Last action

17 December 2024 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Pallone, Frank [D-NJ-6], Rep. Neal, Richard E. [D-MA-1], Rep. Scott, Robert C. "Bobby" [D-VA-3], Rep. Thompson, Mike [D-CA-4], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. Raskin, Jamie [D-MD-8], Rep. Cohen, Steve [D-TN-9], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Stevens, Haley M. [D-MI-11], Rep. Mfume, Kweisi [D-MD-7], Rep. Castor, Kathy [D-FL-14], Rep. Courtney, Joe [D-CT-2], Rep. Tonko, Paul [D-NY-20], Rep. Wild, Susan [D-PA-7], Rep. Trone, David J. [D-MD-6], Rep. Garcia, Robert [D-CA-42], Rep. Kelly, Robin L. [D-IL-2], Sen. Slotkin, Elissa [D-MI], Rep. Titus, Dina [D-NV-1], Rep. Cherfilus-McCormick, Sheila [D-FL-20], Rep. Frankel, Lois [D-FL-22], Rep. McCollum, Betty [D-MN-4], Rep. Ivey, Glenn [D-MD-4], Rep. Schakowsky, Janice D. [D-IL-9], Sen. Kim, Andy [D-NJ], Rep. Larson, John B. [D-CT-1], Rep. Evans, Dwight [D-PA-3], Rep. Keating, William R. [D-MA-9], Rep. Chu, Judy [D-CA-28], Rep. Craig, Angie [D-MN-2], Rep. Bonamici, Suzanne [D-OR-1], Rep. Gomez, Jimmy [D-CA-34], Rep. Beyer, Donald S. [D-VA-8], Rep. Grijalva, Raúl M. [D-AZ-7], Del. Sablan, Gregorio Kilili Camacho [D-MP-At Large], Rep. Goldman, Daniel S. [D-NY-10], Rep. Sarbanes, John P. [D-MD-3], Rep. McClellan, Jennifer L. [D-VA-4], Rep. Lieu, Ted [D-CA-36], Rep. Takano, Mark [D-CA-39], Rep. Meng, Grace [D-NY-6], Rep. DeSaulnier, Mark [D-CA-10], Rep. Dingell, Debbie [D-MI-6], Rep. Morelle, Joseph D. [D-NY-25], Rep. Moore, Gwen [D-WI-4], Rep. Magaziner, Seth [D-RI-2], Rep. Manning, Kathy E. [D-NC-6], Rep. Balint, Becca [D-VT-At Large]

Subjects

Healthcare

Source updated

21 July 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Lowering Drug Costs for American Families Act This bill expands the Medicare Drug Price Negotiation Program to include additional drugs and drugs that are covered under private insurance. It also extends certain rebate requirements for covered drugs under Medicare to drugs that are covered under private insurance. Current law requires the Centers for Medicare & Medicaid Services (CMS) to negotiate maximum prices for brand-name drugs that do not have other generic equivalents and that account for the greatest Medicare spending; the CMS must eventually negotiate the prices of 20 drugs that are covered under Medicare in 2029 and each year thereafter. The bill requires the CMS to negotiate the prices of 50 drugs beginning in 2029. It also applies the negotiated maximum prices under the program to drugs that are covered under private health insurance, unless the insurer opts out. The CMS, Department of Labor, and Department of Treasury must publish a list of insurers that choose to opt out; insurers must also publicly disclose their decision to opt out. Current law also requires drug manufacturers to issue rebates to the CMS for brand-name drugs without generic equivalents under Medicare that cost $100 or more per year per individual and for which prices increase faster than inflation. The bill extends these requirements to drugs that are covered under private insurance.    

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 26 July 2023

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and the Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 26 July 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 26 July 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 28 July 2023

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  5. 17 December 2024

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 26 July 2023

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 26 July 2023

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 26 July 2023

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 78 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.